Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch remain on track.
Gilead’s PrEP Launch Full Speed Ahead Despite Macro Pressures on HIV Space